World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Keith Berelowitz, MSc
Director of Operations

A scientist by training, Keith has worked in clinical research (academic and commercial) for over 22 years, having spent the majority of that period working for Richmond Pharmacology. In his role as Director of Operations at Richmond Pharmacology he is focused on the commercial management of the studies we conduct, the efficiency of the company’s functions and oversight of the healthy volunteer and patient recruitment division, integral to the studies conducted by Richmond Pharmacology.

Having played an operational role in over 250 studies, across the commercial, project and recruitment related management of these studies, his specialist area of interest has focused on the assessment and delivery of early and late phase patient trials in a Phase I environment. Keith has worked with a number of sponsors advising them on the viability of conducting such trials within the UK, a number of which have gone on to be conducted successfully with Richmond Pharmacology.

Keith is a member of the National Research Ethics Service Phase 1 Advisory Group (Health Research Authority, UK), Vice Chair of the Fulham Research Ethics Committee and a member of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI, UK) and one of the UK representative of the EUCROF Extended Executive Board

Back to experts

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more